1-2 of 2
Frankie Holmes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Ian Krop, Vandana Abramson, Marco Colleoni, Tiffany Traina, Frankie Holmes, Laura Garcia-Estevez, Lowell Hart, Ahmad Awada, Claudio Zamagni, Patrick G. Morris, Lee Schwartzberg, Stephen Chan, Ayca Gucalp, Laura Biganzoli, Joyce Steinberg, Lorenzo Sica, Maureen Trudeau, Denka Markova, Jamal Tarazi, Zhou Zhu, Thomas O'Brien, Catherine M. Kelly, Eric Winer, Denise A. Yardley
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6149–6157.
https://doi.org/10.1158/1078-0432.CCR-20-1693
Published: 01 December 2020
View article titled, A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
Open the PDF for A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Ingrid A. Mayer, Aleix Prat, Daniel Egle, Sibel Blau, J. Alejandro Pérez Fidalgo, Michael Gnant, Peter A. Fasching, Marco Colleoni, Antonio C. Wolff, Eric P. Winer, Christian F. Singer, Sara Hurvitz, Laura García Estévez, Peter A. van Dam, Sherko Kümmel, Christoph Mundhenke, Frankie Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-Padilla, Florian D. Vogl, Dalila Sellami, Carlos L. Arteaga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (10): 2975–2987.
https://doi.org/10.1158/1078-0432.CCR-18-3160
Published: 15 May 2019
View article titled, A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Open the PDF for A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) in another window
Includes: Supplementary data